JPS63225314A - Application agent for external use - Google Patents
Application agent for external useInfo
- Publication number
- JPS63225314A JPS63225314A JP7931787A JP7931787A JPS63225314A JP S63225314 A JPS63225314 A JP S63225314A JP 7931787 A JP7931787 A JP 7931787A JP 7931787 A JP7931787 A JP 7931787A JP S63225314 A JPS63225314 A JP S63225314A
- Authority
- JP
- Japan
- Prior art keywords
- weight
- parts
- manufactured
- patch
- plaster
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920000642 polymer Polymers 0.000 claims abstract description 24
- 239000011505 plaster Substances 0.000 claims abstract description 19
- 210000004243 sweat Anatomy 0.000 abstract description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 20
- 206010040880 Skin irritation Diseases 0.000 abstract description 13
- 230000036556 skin irritation Effects 0.000 abstract description 13
- 231100000475 skin irritation Toxicity 0.000 abstract description 13
- 239000003795 chemical substances by application Substances 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 7
- 238000002156 mixing Methods 0.000 abstract description 6
- 230000000704 physical effect Effects 0.000 abstract description 6
- 239000004615 ingredient Substances 0.000 abstract description 4
- 239000002245 particle Substances 0.000 abstract description 4
- 230000008961 swelling Effects 0.000 abstract description 2
- 206010012442 Dermatitis contact Diseases 0.000 abstract 2
- 208000010247 contact dermatitis Diseases 0.000 abstract 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 34
- 239000000126 substance Substances 0.000 description 30
- -1 febrazone Chemical compound 0.000 description 27
- 229920001296 polysiloxane Polymers 0.000 description 26
- 239000000203 mixture Substances 0.000 description 25
- 230000000694 effects Effects 0.000 description 23
- 229960001047 methyl salicylate Drugs 0.000 description 17
- 239000000123 paper Substances 0.000 description 17
- 230000001070 adhesive effect Effects 0.000 description 16
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 15
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 15
- 238000010521 absorption reaction Methods 0.000 description 15
- 239000000853 adhesive Substances 0.000 description 14
- 229960000846 camphor Drugs 0.000 description 13
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 12
- NPERTKSDHFSDLC-UHFFFAOYSA-N ethenol;prop-2-enoic acid Chemical compound OC=C.OC(=O)C=C NPERTKSDHFSDLC-UHFFFAOYSA-N 0.000 description 12
- 239000004744 fabric Substances 0.000 description 12
- 229940057995 liquid paraffin Drugs 0.000 description 12
- 244000043261 Hevea brasiliensis Species 0.000 description 11
- 229940041616 menthol Drugs 0.000 description 11
- 229920003052 natural elastomer Polymers 0.000 description 11
- 229920001194 natural rubber Polymers 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 10
- 238000003892 spreading Methods 0.000 description 10
- 230000007480 spreading Effects 0.000 description 10
- 229920000346 polystyrene-polyisoprene block-polystyrene Polymers 0.000 description 8
- 229920005989 resin Polymers 0.000 description 8
- 239000011347 resin Substances 0.000 description 8
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 239000004745 nonwoven fabric Substances 0.000 description 7
- 229920001083 polybutene Polymers 0.000 description 7
- 230000000699 topical effect Effects 0.000 description 7
- 229920002799 BoPET Polymers 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 6
- 239000004698 Polyethylene Substances 0.000 description 6
- 229920002367 Polyisobutene Polymers 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 6
- 239000010452 phosphate Substances 0.000 description 6
- 229920000573 polyethylene Polymers 0.000 description 6
- 239000011787 zinc oxide Substances 0.000 description 6
- 241000723346 Cinnamomum camphora Species 0.000 description 5
- 229930008380 camphor Natural products 0.000 description 5
- 229960002389 glycol salicylate Drugs 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 229920004939 Cariflex™ Polymers 0.000 description 4
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 4
- 239000004743 Polypropylene Substances 0.000 description 4
- 229960002896 clonidine Drugs 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 229920002674 hyaluronan Polymers 0.000 description 4
- 229960003160 hyaluronic acid Drugs 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 4
- 229960000991 ketoprofen Drugs 0.000 description 4
- 231100000344 non-irritating Toxicity 0.000 description 4
- RGOVYLWUIBMPGK-UHFFFAOYSA-N nonivamide Chemical compound CCCCCCCCC(=O)NCC1=CC=C(O)C(OC)=C1 RGOVYLWUIBMPGK-UHFFFAOYSA-N 0.000 description 4
- 229920001155 polypropylene Polymers 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 229920003169 water-soluble polymer Polymers 0.000 description 4
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- LRCFXGAMWKDGLA-UHFFFAOYSA-N dioxosilane;hydrate Chemical compound O.O=[Si]=O LRCFXGAMWKDGLA-UHFFFAOYSA-N 0.000 description 3
- 229920001971 elastomer Polymers 0.000 description 3
- 235000010985 glycerol esters of wood rosin Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 229960002508 pindolol Drugs 0.000 description 3
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 3
- 229920000728 polyester Polymers 0.000 description 3
- 239000005060 rubber Substances 0.000 description 3
- 229960004029 silicic acid Drugs 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- VSKJLJHPAFKHBX-UHFFFAOYSA-N 2-methylbuta-1,3-diene;styrene Chemical compound CC(=C)C=C.C=CC1=CC=CC=C1.C=CC1=CC=CC=C1 VSKJLJHPAFKHBX-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 229920006243 acrylic copolymer Polymers 0.000 description 2
- 230000001760 anti-analgesic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 2
- 229950002568 bucumolol Drugs 0.000 description 2
- CIJVBYRUFLGDHY-UHFFFAOYSA-N bucumolol Chemical compound O1C(=O)C=CC2=C1C(OCC(O)CNC(C)(C)C)=CC=C2C CIJVBYRUFLGDHY-UHFFFAOYSA-N 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 229960005309 estradiol Drugs 0.000 description 2
- 229930182833 estradiol Natural products 0.000 description 2
- 229960004930 fludiazepam Drugs 0.000 description 2
- ROYOYTLGDLIGBX-UHFFFAOYSA-N fludiazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F ROYOYTLGDLIGBX-UHFFFAOYSA-N 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000001879 gelation Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 229920006267 polyester film Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 229960003101 pranoprofen Drugs 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229920006132 styrene block copolymer Polymers 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000002747 voluntary effect Effects 0.000 description 2
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- UHSXRTHJCJGEKG-UQKRIMTDSA-N (1s)-1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-2-ium-6,7-diol;chloride Chemical compound Cl.COC1=C(OC)C(OC)=CC(C[C@H]2C3=CC(O)=C(O)C=C3CCN2)=C1 UHSXRTHJCJGEKG-UQKRIMTDSA-N 0.000 description 1
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-MHPPCMCBSA-N (4r)-4,7,7-trimethylbicyclo[2.2.1]heptan-3-one Chemical compound C1C[C@@]2(C)C(=O)CC1C2(C)C DSSYKIVIOFKYAU-MHPPCMCBSA-N 0.000 description 1
- QHZUABXEBRGBLP-LKWYKXIFSA-N (6aR,9R,10aR)-N-[(2R,4R,9aS,9bR)-4-benzyl-9b-hydroxy-3,5-dioxo-2-propan-2-yl-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide (6aR,9R,10aR)-N-[(2R,4R,9aS,9bR)-9b-hydroxy-3,5-dioxo-2,4-di(propan-2-yl)-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide (6aR,10aR)-N-[(2S,4S,9bS)-9b-hydroxy-4-(2-methylpropyl)-3,5-dioxo-2-propan-2-yl-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)C4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)C)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2CC(CN(C)[C@@H]2C2)C(=O)N[C@@]3(C(=O)C4[C@@H](C(N5CCCC5[C@@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(C21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C(C)C)C1=CC=CC=C1 QHZUABXEBRGBLP-LKWYKXIFSA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- BFUXUGOZJVHVMR-UHFFFAOYSA-N 1,1-dioxo-3,4-dihydro-2h-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound N1CNS(=O)(=O)C2=CC(S(=O)(=O)N)=CC=C21 BFUXUGOZJVHVMR-UHFFFAOYSA-N 0.000 description 1
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical group N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 description 1
- WYUYEJNGHIOFOC-VVTVMFAVSA-N 2-[(z)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine;hydrochloride Chemical compound Cl.C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C\CN1CCCC1 WYUYEJNGHIOFOC-VVTVMFAVSA-N 0.000 description 1
- JIEKMACRVQTPRC-UHFFFAOYSA-N 2-[4-(4-chlorophenyl)-2-phenyl-5-thiazolyl]acetic acid Chemical compound OC(=O)CC=1SC(C=2C=CC=CC=2)=NC=1C1=CC=C(Cl)C=C1 JIEKMACRVQTPRC-UHFFFAOYSA-N 0.000 description 1
- KXGFMDJXCMQABM-UHFFFAOYSA-N 2-methoxy-6-methylphenol Chemical compound [CH]OC1=CC=CC([CH])=C1O KXGFMDJXCMQABM-UHFFFAOYSA-N 0.000 description 1
- PUHLHLQBIFRKRD-CSKARUKUSA-N 5-methyl-2-[(E)-2-phenylethenyl]-1,3-benzoxazole Chemical compound N=1C2=CC(C)=CC=C2OC=1\C=C\C1=CC=CC=C1 PUHLHLQBIFRKRD-CSKARUKUSA-N 0.000 description 1
- BKYKPTRYDKTTJY-UHFFFAOYSA-N 6-chloro-3-(cyclopentylmethyl)-1,1-dioxo-3,4-dihydro-2H-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1CCCC1 BKYKPTRYDKTTJY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 235000002568 Capsicum frutescens Nutrition 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- HHJIUUAMYGBVSD-YTFFSALGSA-N Diflucortolone valerate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)COC(=O)CCCC)[C@@]2(C)C[C@@H]1O HHJIUUAMYGBVSD-YTFFSALGSA-N 0.000 description 1
- 240000001879 Digitalis lutea Species 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- SWECWXGUJQLXJF-BTJKTKAUSA-N Dimetindene maleate Chemical compound OC(=O)\C=C/C(O)=O.CN(C)CCC=1CC2=CC=CC=C2C=1C(C)C1=CC=CC=N1 SWECWXGUJQLXJF-BTJKTKAUSA-N 0.000 description 1
- ZVXBAHLOGZCFTP-UHFFFAOYSA-N Efloxate Chemical compound C=1C(OCC(=O)OCC)=CC=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 ZVXBAHLOGZCFTP-UHFFFAOYSA-N 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- BALXUFOVQVENIU-GNAZCLTHSA-N Ephedrine hydrochloride Chemical compound Cl.CN[C@@H](C)[C@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-GNAZCLTHSA-N 0.000 description 1
- VXLCNTLWWUDBSO-UHFFFAOYSA-N Ethiazide Chemical compound ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)NC(CC)NC2=C1 VXLCNTLWWUDBSO-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
- POPFMWWJOGLOIF-XWCQMRHXSA-N Flurandrenolide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O POPFMWWJOGLOIF-XWCQMRHXSA-N 0.000 description 1
- WMFSSTNVXWNLKI-UHFFFAOYSA-N Flutazolam Chemical compound O1CCN2CC(=O)N(CCO)C3=CC=C(Cl)C=C3C21C1=CC=CC=C1F WMFSSTNVXWNLKI-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- XDKCGKQHVBOOHC-UHFFFAOYSA-N Haloxazolam Chemical compound FC1=CC=CC=C1C1(C2=CC(Br)=CC=C2NC(=O)C2)N2CCO1 XDKCGKQHVBOOHC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- ACEWLPOYLGNNHV-UHFFFAOYSA-N Ibuprofen piconol Chemical compound C1=CC(CC(C)C)=CC=C1C(C)C(=O)OCC1=CC=CC=N1 ACEWLPOYLGNNHV-UHFFFAOYSA-N 0.000 description 1
- 229920002633 Kraton (polymer) Polymers 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- CESYKOGBSMNBPD-UHFFFAOYSA-N Methyclothiazide Chemical compound ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CCl)NC2=C1 CESYKOGBSMNBPD-UHFFFAOYSA-N 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 239000006002 Pepper Substances 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 235000017804 Piper guineense Nutrition 0.000 description 1
- 244000203593 Piper nigrum Species 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 239000005062 Polybutadiene Substances 0.000 description 1
- CYLWJCABXYDINA-UHFFFAOYSA-N Polythiazide Polymers ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CSCC(F)(F)F)NC2=C1 CYLWJCABXYDINA-UHFFFAOYSA-N 0.000 description 1
- MWQCHHACWWAQLJ-UHFFFAOYSA-N Prazepam Chemical compound O=C1CN=C(C=2C=CC=CC=2)C2=CC(Cl)=CC=C2N1CC1CC1 MWQCHHACWWAQLJ-UHFFFAOYSA-N 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 241001247145 Sebastes goodei Species 0.000 description 1
- 239000002174 Styrene-butadiene Substances 0.000 description 1
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- RSLNRVYIRDVHLY-UHFFFAOYSA-N Tulobuterol hydrochloride Chemical compound [Cl-].CC(C)(C)[NH2+]CC(O)C1=CC=CC=C1Cl RSLNRVYIRDVHLY-UHFFFAOYSA-N 0.000 description 1
- JDLSRXWHEBFHNC-UHFFFAOYSA-N Ufenamate Chemical compound CCCCOC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 JDLSRXWHEBFHNC-UHFFFAOYSA-N 0.000 description 1
- QYKIQEUNHZKYBP-UHFFFAOYSA-N Vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002998 adhesive polymer Substances 0.000 description 1
- BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 description 1
- 229960002213 alprenolol Drugs 0.000 description 1
- PAZJSJFMUHDSTF-UHFFFAOYSA-N alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 description 1
- 229960003099 amcinonide Drugs 0.000 description 1
- ILKJAFIWWBXGDU-MOGDOJJUSA-N amcinonide Chemical compound O([C@@]1([C@H](O2)C[C@@H]3[C@@]1(C[C@H](O)[C@]1(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]13)C)C(=O)COC(=O)C)C12CCCC1 ILKJAFIWWBXGDU-MOGDOJJUSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- YEJAJYAHJQIWNU-UHFFFAOYSA-N azelastine hydrochloride Chemical compound Cl.C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 YEJAJYAHJQIWNU-UHFFFAOYSA-N 0.000 description 1
- 229960004335 azelastine hydrochloride Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- 229950004580 benzyl nicotinate Drugs 0.000 description 1
- QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 description 1
- 229960000330 bupranolol Drugs 0.000 description 1
- HQIRNZOQPUAHHV-UHFFFAOYSA-N bupranolol Chemical compound CC1=CC=C(Cl)C(OCC(O)CNC(C)(C)C)=C1 HQIRNZOQPUAHHV-UHFFFAOYSA-N 0.000 description 1
- 229960001889 buprenorphine hydrochloride Drugs 0.000 description 1
- UAIXRPCCYXNJMQ-RZIPZOSSSA-N buprenorphine hydrochlorie Chemical compound [Cl-].C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)C[NH+]2CC1CC1 UAIXRPCCYXNJMQ-RZIPZOSSSA-N 0.000 description 1
- MTAZNLWOLGHBHU-UHFFFAOYSA-N butadiene-styrene rubber Chemical compound C=CC=C.C=CC1=CC=CC=C1 MTAZNLWOLGHBHU-UHFFFAOYSA-N 0.000 description 1
- GMTYREVWZXJPLF-AFHUBHILSA-N butorphanol D-tartrate Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O.N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 GMTYREVWZXJPLF-AFHUBHILSA-N 0.000 description 1
- 229960001590 butorphanol tartrate Drugs 0.000 description 1
- 229940007061 capsicum extract Drugs 0.000 description 1
- 239000001943 capsicum frutescens fruit extract Substances 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 229960000456 carbinoxamine maleate Drugs 0.000 description 1
- GVNWHCVWDRNXAZ-BTJKTKAUSA-N carbinoxamine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 GVNWHCVWDRNXAZ-BTJKTKAUSA-N 0.000 description 1
- 229960001222 carteolol Drugs 0.000 description 1
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229940046978 chlorpheniramine maleate Drugs 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
- DERZBLKQOCDDDZ-JLHYYAGUSA-N cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 description 1
- 229960000876 cinnarizine Drugs 0.000 description 1
- OPXKTCUYRHXSBK-UHFFFAOYSA-N clenbuterol hydrochloride Chemical compound Cl.CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 OPXKTCUYRHXSBK-UHFFFAOYSA-N 0.000 description 1
- 229960001399 clenbuterol hydrochloride Drugs 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960003932 cloxazolam Drugs 0.000 description 1
- ZIXNZOBDFKSQTC-UHFFFAOYSA-N cloxazolam Chemical compound C12=CC(Cl)=CC=C2NC(=O)CN2CCOC21C1=CC=CC=C1Cl ZIXNZOBDFKSQTC-UHFFFAOYSA-N 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000035597 cooling sensation Effects 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- BMCQMVFGOVHVNG-TUFAYURCSA-N cortisol 17-butyrate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O BMCQMVFGOVHVNG-TUFAYURCSA-N 0.000 description 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 229960003206 cyclopenthiazide Drugs 0.000 description 1
- OBATZBGFDSVCJD-UHFFFAOYSA-N de-O-acetyl-lanatoside C Natural products CC1OC(OC2CC3C(C4C(C5(CCC(C5(C)C(O)C4)C=4COC(=O)C=4)O)CC3)(C)CC2)CC(O)C1OC(OC1C)CC(O)C1OC(OC1C)CC(O)C1OC1OC(CO)C(O)C(O)C1O OBATZBGFDSVCJD-UHFFFAOYSA-N 0.000 description 1
- 229960001324 deslanoside Drugs 0.000 description 1
- OBATZBGFDSVCJD-LALPQLPRSA-N deslanoside Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@H]1[C@@H](O)C[C@@H](O[C@@H]1C)O[C@@H]1C[C@@H]2[C@]([C@@H]3[C@H]([C@]4(CC[C@@H]([C@@]4(C)[C@H](O)C3)C=3COC(=O)C=3)O)CC2)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O OBATZBGFDSVCJD-LALPQLPRSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 229960003970 diflucortolone valerate Drugs 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- KBEZZLAAKIIPFK-NJAFHUGGSA-N dimemorfan Chemical compound C1C2=CC=C(C)C=C2[C@@]23CCN(C)[C@@H]1[C@H]2CCCC3 KBEZZLAAKIIPFK-NJAFHUGGSA-N 0.000 description 1
- 229960001056 dimemorfan Drugs 0.000 description 1
- 229940099401 dimethindene maleate Drugs 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 229960003859 efloxate Drugs 0.000 description 1
- OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 description 1
- 229960000309 enalapril maleate Drugs 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 229960002534 ephedrine hydrochloride Drugs 0.000 description 1
- 229960002336 estazolam Drugs 0.000 description 1
- CDCHDCWJMGXXRH-UHFFFAOYSA-N estazolam Chemical compound C=1C(Cl)=CC=C(N2C=NN=C2CN=2)C=1C=2C1=CC=CC=C1 CDCHDCWJMGXXRH-UHFFFAOYSA-N 0.000 description 1
- RFWTZQAOOLFXAY-BZDYCCQFSA-N estradiol enanthate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCC)[C@@]1(C)CC2 RFWTZQAOOLFXAY-BZDYCCQFSA-N 0.000 description 1
- 229950004659 estradiol enanthate Drugs 0.000 description 1
- 229950007164 ethiazide Drugs 0.000 description 1
- UQXKXGWGFRWILX-UHFFFAOYSA-N ethylene glycol dinitrate Chemical compound O=N(=O)OCCON(=O)=O UQXKXGWGFRWILX-UHFFFAOYSA-N 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229960000192 felbinac Drugs 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- 229960002679 fentiazac Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229960004511 fludroxycortide Drugs 0.000 description 1
- 229960001347 fluocinolone acetonide Drugs 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- 229960000785 fluocinonide Drugs 0.000 description 1
- 229960001048 fluorometholone Drugs 0.000 description 1
- FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 description 1
- 229960002690 fluphenazine Drugs 0.000 description 1
- 229960003528 flurazepam Drugs 0.000 description 1
- SAADBVWGJQAEFS-UHFFFAOYSA-N flurazepam Chemical compound N=1CC(=O)N(CCN(CC)CC)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F SAADBVWGJQAEFS-UHFFFAOYSA-N 0.000 description 1
- 229950009354 flutazolam Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 229950002502 haloxazolam Drugs 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960001067 hydrocortisone acetate Drugs 0.000 description 1
- 229960001524 hydrocortisone butyrate Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 229950005954 ibuprofen piconol Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229950008838 indenolol Drugs 0.000 description 1
- MPGBPFMOOXKQRX-UHFFFAOYSA-N indenolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1C=CC2 MPGBPFMOOXKQRX-UHFFFAOYSA-N 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 229960003630 ketotifen fumarate Drugs 0.000 description 1
- YNQQEYBLVYAWNX-WLHGVMLRSA-N ketotifen fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 YNQQEYBLVYAWNX-WLHGVMLRSA-N 0.000 description 1
- 229960004400 levonorgestrel Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960002373 loxoprofen Drugs 0.000 description 1
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 229960003739 methyclothiazide Drugs 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229960001293 methylprednisolone acetate Drugs 0.000 description 1
- PLBHSZGDDKCEHR-LFYFAGGJSA-N methylprednisolone acetate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(C)=O)CC[C@H]21 PLBHSZGDDKCEHR-LFYFAGGJSA-N 0.000 description 1
- 229960003746 metildigoxin Drugs 0.000 description 1
- IYJMSDVSVHDVGT-PEQKVOOWSA-N metildigoxin Chemical compound O1[C@H](C)[C@@H](OC)[C@@H](O)C[C@@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O IYJMSDVSVHDVGT-PEQKVOOWSA-N 0.000 description 1
- AQCHWTWZEMGIFD-UHFFFAOYSA-N metolazone Chemical compound CC1NC2=CC(Cl)=C(S(N)(=O)=O)C=C2C(=O)N1C1=CC=CC=C1C AQCHWTWZEMGIFD-UHFFFAOYSA-N 0.000 description 1
- 229960002817 metolazone Drugs 0.000 description 1
- 229950000412 mexazolam Drugs 0.000 description 1
- ANUCDXCTICZJRH-UHFFFAOYSA-N mexazolam Chemical compound C=1C=C(Cl)C=C2C=1NC(=O)CN1C(C)COC21C1=CC=CC=C1Cl ANUCDXCTICZJRH-UHFFFAOYSA-N 0.000 description 1
- 229960004027 molsidomine Drugs 0.000 description 1
- XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical compound O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 description 1
- 229960002497 nicorandil Drugs 0.000 description 1
- LBHIOVVIQHSOQN-UHFFFAOYSA-N nicorandil Chemical compound [O-][N+](=O)OCCNC(=O)C1=CC=CN=C1 LBHIOVVIQHSOQN-UHFFFAOYSA-N 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 229950001981 nimetazepam Drugs 0.000 description 1
- GWUSZQUVEVMBPI-UHFFFAOYSA-N nimetazepam Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1 GWUSZQUVEVMBPI-UHFFFAOYSA-N 0.000 description 1
- 229920006284 nylon film Polymers 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940060184 oil ingredients Drugs 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- 229960004535 oxazepam Drugs 0.000 description 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
- 229950006124 oxazolam Drugs 0.000 description 1
- VCCZBYPHZRWKFY-XIKOKIGWSA-N oxazolam Chemical compound C1([C@]23C4=CC(Cl)=CC=C4NC(=O)CN2C[C@H](O3)C)=CC=CC=C1 VCCZBYPHZRWKFY-XIKOKIGWSA-N 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229940116257 pepper extract Drugs 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 229920001568 phenolic resin Polymers 0.000 description 1
- 239000005011 phenolic resin Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920002857 polybutadiene Polymers 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 229960005483 polythiazide Drugs 0.000 description 1
- 229920000046 polythiazide Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960004856 prazepam Drugs 0.000 description 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
- 229960001289 prazosin Drugs 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- BOFKYYWJAOZDPB-FZNHGJLXSA-N prednival Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O BOFKYYWJAOZDPB-FZNHGJLXSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960001309 procaine hydrochloride Drugs 0.000 description 1
- 229960002288 procaterol Drugs 0.000 description 1
- FKNXQNWAXFXVNW-BLLLJJGKSA-N procaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)[C@@H](NC(C)C)CC FKNXQNWAXFXVNW-BLLLJJGKSA-N 0.000 description 1
- 229960003111 prochlorperazine Drugs 0.000 description 1
- WIKYUJGCLQQFNW-UHFFFAOYSA-N prochlorperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 WIKYUJGCLQQFNW-UHFFFAOYSA-N 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000011115 styrene butadiene Substances 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- 229920001909 styrene-acrylic polymer Polymers 0.000 description 1
- 229960004492 suprofen Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002522 swelling effect Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960002784 thioridazine Drugs 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 229960001312 tiaprofenic acid Drugs 0.000 description 1
- GUHPRPJDBZHYCJ-UHFFFAOYSA-N tiaprofenic acid Chemical compound S1C(C(C(O)=O)C)=CC=C1C(=O)C1=CC=CC=C1 GUHPRPJDBZHYCJ-UHFFFAOYSA-N 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- 229960000896 tipepidine Drugs 0.000 description 1
- NZHGWWWHIYHZNX-CSKARUKUSA-N tranilast Chemical compound C1=C(OC)C(OC)=CC=C1\C=C\C(=O)NC1=CC=CC=C1C(O)=O NZHGWWWHIYHZNX-CSKARUKUSA-N 0.000 description 1
- 229960005342 tranilast Drugs 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 229960003386 triazolam Drugs 0.000 description 1
- JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 1
- 229960001593 triprolidine hydrochloride Drugs 0.000 description 1
- 229960004846 tulobuterol hydrochloride Drugs 0.000 description 1
- 229960004747 ubidecarenone Drugs 0.000 description 1
- 229950010121 ufenamate Drugs 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
【発明の詳細な説明】
皇栗上鬼丑貝圀!
本発明は吸水高分子を配合することにより、気触れの発
生が著しく軽減され、且つ、皮膚刺激の少ない外用貼付
剤に関するものである。[Detailed Description of the Invention] Emperor Chestnut-jo Oni Ushikai Kuni! The present invention relates to an external patch that significantly reduces the occurrence of skin irritation and causes less skin irritation by incorporating a water-absorbing polymer.
皿米肢歪
従来、外用貼付剤としては粘着性高分子に薬物を含有さ
せ柔軟性のある布、不織布、もしくは各種プラスチック
フィルムなどの支持体上に直接、あるいは間接的に展延
した製剤として、プラスター剤、パップ剤、テープ剤等
がある。又、薬物を含有しない貼付剤として、サージカ
ルテープ、絆創膏、テーピング等が用いられてきた。こ
れらの外用貼付剤は、その使用にあたり剥離時の毛の引
っ張り等の物理的作用、長時間貼付によるムレ。Traditionally, topical patches have been prepared by containing drugs in adhesive polymers and spreading them directly or indirectly onto a support such as flexible cloth, nonwoven fabric, or various plastic films. There are plasters, poultices, tapes, etc. In addition, surgical tape, adhesive plaster, taping, etc. have been used as drug-free patches. When using these external patches, there are physical effects such as hair pulling when removed, and stuffiness due to long-term application.
発汗等の生理的作用による発赤、気触れ等の副作用の発
現が問題とされていた。The occurrence of side effects such as redness and skin irritation due to physiological effects such as sweating has been a problem.
その主たる原因は、従来の外用貼付剤は通気性。The main reason for this is that conventional topical patches are breathable.
透湿性あるいは吸湿性がなく、これを皮膚に貼付した場
合、皮膚表面の杼口閉塞を引き起こし、水分の揮散が止
まってしまい、汗や分泌物に含まれる刺激成分により気
触れが発生している。It does not have moisture permeability or absorbency, and when applied to the skin, it causes the skin surface to become clogged, stopping moisture from evaporating, and causing irritation due to the irritating components contained in sweat and secretions. .
一方、これらの問題を解決する手段として種々の試みが
なされている。On the other hand, various attempts have been made to solve these problems.
例えば、特公昭58−52251号公報には膏体に通気
孔をあける方法が提示されている。又特開昭58−47
21号公報、特開昭60−56911号公報、特開昭6
0−23312号公報等には気触れ防止あるいは皮膚刺
激低減のための薬物配合が示されている。特公昭59−
19528号公報には基剤に特殊な処理をほどこし、皮
膚刺激を低減させる方法が提示されている。しかし、い
ずれの場合においても実用性に問題があったり、製造工
程が複雑であったり、又、その効果も不充分なものであ
る。又、気触れの主たる原因である汗や分泌物を基剤中
に吸汗あるいは吸着させる方法も試みられており、例え
ば、特公昭54−44688ではPVAやセルロース類
を配合する方法、実開昭55−19258では多糖類ガ
ムを配合、特公昭58−23846及び特開昭60−4
1968ではアクリル共重合体を配合する方法が開示さ
れている。又、特開昭60−123416及び特開昭6
0−123417では、水溶性高分子及び多糖類を配合
することによって貼付剤に吸汗性あるいは水分透過性を
付与し、皮膚刺激の低減が試みられている。しかしなが
ら、実際上は、逆に水溶性であるがゆえに膏体が汗で溶
は出す場合があり、更には、いずれの場合においても吸
水、吸汗能力としては不充分で、せいぜい1〜10%程
度の吸水能力でしかないために完全には汗あるいは分泌
物を吸着しておらず、従って、吸着されなかった汗や分
泌物による気触れが発生している現状である。For example, Japanese Patent Publication No. 58-52251 discloses a method of making ventilation holes in a plaster. Also, Japanese Patent Publication No. 58-47
No. 21, JP-A-60-56911, JP-A-Sho 6
No. 0-23312 and the like disclose drug combinations for preventing exposure or reducing skin irritation. Special Public Service 1984-
Japanese Patent No. 19528 proposes a method of reducing skin irritation by subjecting the base material to special treatment. However, in either case, there are problems in practicality, the manufacturing process is complicated, and the effects are insufficient. In addition, methods have been attempted in which sweat and secretions, which are the main causes of skin irritation, are absorbed or adsorbed into the base material. -19258 contains polysaccharide gum, Japanese Patent Publication No. 58-23846 and Japanese Patent Application Publication No. 60-4
In 1968, a method for compounding acrylic copolymers was disclosed. Also, JP-A-60-123416 and JP-A-6
No. 0-123417 attempts to reduce skin irritation by imparting sweat absorbency or water permeability to a patch by incorporating a water-soluble polymer and a polysaccharide. However, in reality, since it is water-soluble, the plaster may dissolve with sweat, and in any case, its water absorption and sweat absorption ability is insufficient, at most 1 to 10%. Because the water absorbing capacity is only 1,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000.
以上の如く、種々の方法が試みられているにもかかわら
ず、実用的にはほど遠く、結局未だ気触れのない理想的
な外用貼付剤は出現していないのが現状である。As mentioned above, although various methods have been tried, they are far from practical, and at present, an ideal external patch that does not cause any discomfort has yet appeared.
口 を解゛するための手段
本願発明者らは、この様な状況に鑑み、従来にない気触
れのない外用貼付剤を開発すべく、前述の種々の改良方
法の中で吸汗性を向上させる点に着目し、鋭意研究を重
ねた結果、吸水高分子を配合する事により、目的を達成
できることを見出したものである。すなわち、本願発明
は膏体成分中に必須成分として吸水高分子1〜20重量
%を配合することを特徴とする外用貼付剤に関するもの
であり、詳細には、吸水高分子を必須成分として配合し
、皮膚から出た汗あるいは分泌物を吸収。In view of this situation, the inventors of the present application have improved sweat absorption among the various improvement methods described above, in order to develop a topical patch that is unprecedented and has no unpleasant sensations. After focusing on this point and conducting extensive research, we discovered that the objective could be achieved by incorporating a water-absorbing polymer. That is, the present invention relates to a patch for external use characterized in that 1 to 20% by weight of a water-absorbing polymer is blended as an essential component in the plaster component. , absorbs sweat or secretions from the skin.
吸着させる事により、従来の配合剤である水溶性高分子
2多m類ガムあるいはアクリル共重合体等を配合するこ
とで解決できなかった問題、つまり、ムレ又は気触れ等
の副作用が著しく軽減され、しかも剥離時の痛みを緩和
した外用貼付剤を開発し、本発明を完成するに至った。By adsorbing it, the problems that could not be solved by conventional compounding agents such as water-soluble polymer 2-M gum or acrylic copolymer, such as side effects such as stuffiness or feeling, are significantly reduced. The inventors have developed an external patch that alleviates pain when peeled off, and have completed the present invention.
従来、吸水高分子は農業用あるいは土木用止水剤等に用
いられ、吸水・膨潤効果を出すため、膏体に多量に配合
して使用されている。しかし気触れを防止する目的で外
用貼付剤に配合された例はなく、それを示唆する公知文
献は見あたらない。Conventionally, water-absorbing polymers have been used in water-stopping agents for agricultural and civil engineering applications, and in order to produce water-absorbing and swelling effects, they have been incorporated in large amounts into plasters. However, there have been no examples of it being incorporated into external patches for the purpose of preventing skin irritation, and no known literature suggesting this has been found.
吸水するには普通、多量の吸水高分子を必要とするため
、これを膏体に配合した場合、吸水後は膏体が著しく膨
潤し、その結果、物性破壊を引き起こしてしまう。それ
ゆえ今まで基剤成分としては配合する事ができなかった
のである。Normally, a large amount of water-absorbing polymer is required to absorb water, so when this is added to a plaster, the plaster swells significantly after absorbing water, resulting in destruction of its physical properties. Therefore, until now it has not been possible to incorporate it as a base component.
しかしながら、本願発明者らは以外にも少ない配合量で
、充分に吸汗し、気触れ防止効果がある事を見出したの
である。つまり、後述する特定の配合量においてのみ充
分に吸汗した上に、吸汗後も膏体は膨潤破壊されず、且
つ、汗を吸う事により、膏体全体が適度にゲル化される
ため、毛の引っ張り等の物理的作用をも軽減されたので
ある。However, the inventors of the present invention have discovered that even with a small amount of addition, it can sufficiently absorb sweat and have the effect of preventing skin contact. In other words, in addition to sufficient sweat absorption only at a specific blending amount, which will be described later, the plaster does not swell and break even after sweat absorption, and the entire plaster gels appropriately by absorbing sweat, making it possible to absorb hair. Physical effects such as tension were also reduced.
即ち、吸水高分子を気触れ防止及び粘着性の改善を目的
とした医療貼付製剤として用いたのは本願発明者らが最
初に行った新知見である。That is, the use of a water-absorbing polymer as a medical patch preparation for the purpose of preventing exposure and improving adhesiveness is the first new finding made by the inventors of the present invention.
本発明の必須成分である吸水高分子の配合量は重量%で
1〜20%、好ましくは1〜8%が望ましい、1%未満
では、充分な吸水力が期待できず、汗や分泌物による気
触れが発生する。The amount of the water-absorbing polymer, which is an essential component of the present invention, is preferably 1 to 20% by weight, preferably 1 to 8%. If it is less than 1%, sufficient water absorption cannot be expected, and sweat and secretions A feeling arises.
一方20%以上では、吸水力は充分であるが、膏体の凝
集力の低下及び粘着力の低下が大きく、剥がれやすくな
ってしまう。On the other hand, if it is 20% or more, the water absorption power is sufficient, but the cohesive force and adhesive force of the plaster are greatly reduced, and it becomes easy to peel off.
次に吸水高分子について具体的に説明すると、吸水高分
子とは自重の10倍以上の水を吸水あるいはゲル化、膨
潤するものであって、例えば水溶性ポリマーに軽度な架
橋結合を導入したものが、適宜単独もしくは2種以上の
混合でもって処方される。例えば■三洋化成の商品名サ
ンウェットIM−300、サンウェットIM−300M
PS。Next, to explain specifically about water-absorbing polymers, water-absorbing polymers are those that absorb, gel, or swell more than 10 times their own weight in water, such as water-soluble polymers with mild cross-linking. may be formulated either singly or in combination of two or more. For example, ■ Sanyo Chemical's product name Sunwet IM-300, Sunwet IM-300M.
P.S.
サンウェフト1M−1000,サンウエフトIM−10
0OMPS等、麹製鉄化学の商品名アクアキープ4S、
アクアキープ4SH等、■住人化学の商品名スミカゲル
5P−520、スミカゲル5P−540、スミカゲルN
100、スミカゲルNP−1020,スミカゲルNP−
1040等、■クラレのKlゲル−201に、Klゲル
−201に−F2等、■荒川化学の商品名アラソーブ8
00、アラソーブ800F等であり、好ましくは軽度の
架橋結合を導入したものが好適に用いられる。Sunweft 1M-1000, Sunweft IM-10
0OMPS etc., Koji Seitetsu Chemical's product name Aqua Keep 4S,
Aqua Keep 4SH, etc., Sumikagel 5P-520, Sumikagel 5P-540, Sumikagel N, sold by Sumika Kagaku.
100, Sumikagel NP-1020, Sumikagel NP-
1040, etc., ■ Kuraray's Kl Gel-201, Kl Gel-201 -F2, etc., ■ Arakawa Chemical's trade name Arasorb 8
00, Arasorb 800F, etc., and those having a slight crosslinking are preferably used.
中でも、サンウェットIM−300MPS、サンウェッ
トIM−1000MPS、スミカゲルNP−1020、
スミカゲルNP−1040、KIゲル−201に−F2
、アラソーブFは特に好ましい。吸水高分子を選択する
にあたっては、粒子径も重要な要因となる。膏体中に均
一に分散させ、かつ優れた吸水性・吸汗性および良好な
粘着特性、すなわち、粘着力、接着力、凝集力のバラン
スを良好に保つためには、吸水高分子の粒子径はできる
だけ小さい方が好ましい、具体的には100μ以下、特
に好ましくは30μ以下である。Among them, Sunwet IM-300MPS, Sunwet IM-1000MPS, Sumikagel NP-1020,
Sumikagel NP-1040, KI gel-201-F2
, Arasorb F is particularly preferred. Particle size is also an important factor when selecting a water-absorbing polymer. The particle size of the water-absorbing polymer must be adjusted to ensure uniform dispersion in the plaster and to maintain excellent water absorption, sweat absorption, and adhesive properties, that is, a good balance of adhesive strength, adhesion, and cohesion. It is preferably as small as possible, specifically 100μ or less, particularly preferably 30μ or less.
次に、本発明を実施するにあたって、貼付剤として用い
られる基剤成分としての高分子系の基剤は別に制約はな
く、例えばシリコーン系、スチレン−イソプレン−スチ
レン系、スチレン−ブタジェン系、アクリル系、ビニル
エーテル系、天然ゴム系、ウレタン系、ポリイソブチレ
ン系゛等の高分子物質が用いられ、これらの高分子物質
が膏体中に含有される好ましい量は、10〜90重量%
であるが、その中でも天然ゴム、スチレン−イソプレン
−スチレン系、ポリイソブチレン等いわゆるジエン系の
ゴムの場合は20〜40重量%が特に好ましい、さらに
従来公知の粘着付与剤、例えばロジン系樹脂〔エステル
ガム(荒川化学)、ハリニスター(播磨化成)、ハリタ
ック(播磨化成)〕、テルペン系樹脂(YSレジン(安
原油脂)、ピコライト(バーキュリーズ)〕、石油系樹
脂〔アルコン(荒川化学)、レガレッツ(バーキュリー
ズ)、エスコレッッ(エクソン)、ウィングタック(グ
ツドイヤー)〕、フェノール系樹脂、キシレン系樹脂等
が50重量%以下でもって使用される。但し、高分子基
剤としてアクリル系を使用する場合、種類によっては充
分に粘着性を有するので、種類に応じて使用の有無は判
断される。その地回塑剤、充填剤、安定剤が適宜配合さ
れても良い。他に金属酸化物として、酸化亜鉛、酸化ア
ルミニウム、酸化マグネシウム、酸化鉄等が適宜配合さ
れても良い。これらを添加することにより、膏体の吸水
・吸汗後の膨潤による破壊現象を防ぐことができる。Next, in carrying out the present invention, there are no particular restrictions on the polymeric base used as the base component for the patch, and examples include silicone, styrene-isoprene-styrene, styrene-butadiene, and acrylic. , vinyl ether type, natural rubber type, urethane type, polyisobutylene type, etc. are used, and the preferred amount of these polymer substances contained in the plaster is 10 to 90% by weight.
However, in the case of so-called diene-based rubbers such as natural rubber, styrene-isoprene-styrene-based rubber, and polyisobutylene, the amount is particularly preferably 20 to 40% by weight. Gum (Arakawa Chemical), Harinister (Harima Kasei), Haritac (Harima Kasei)], Terpene resins (YS resin (cheap crude oil), Picolite (Vercules)), Petroleum resins [Alcon (Arakawa Chemical), Regalets (Vercules) , Escolette (Exxon), Wingtac (Gutsdoyer)], phenolic resin, xylene resin, etc. are used in an amount of 50% by weight or less.However, when using acrylic as the polymer base, depending on the type, it may be sufficient. has adhesive properties, so whether or not to use it is determined depending on the type. Plasticizers, fillers, and stabilizers may be added as appropriate. Other metal oxides include zinc oxide and aluminum oxide. , magnesium oxide, iron oxide, etc. may be appropriately blended.By adding these, it is possible to prevent destruction of the plaster due to swelling after absorption of water and sweat.
又、含有される薬物は経皮吸収性薬物であれば特に限定
はなく、例えば皮膚刺激剤及び鎮痛消炎剤として、サリ
チル酸、サリチル酸メチル、サリチル酸グリコール、!
−メントール、カンフル、ハツカ油、チモール、ニコチ
ン酸ベンジルエステル、トウガラシエキス、カブサイシ
ン、ノニル酸ワニリルアミド、フェルビナク、フルフェ
ナム酸ブチル、ピロキシカム、インドメタシン、ケトプ
ロフェン、プラノプロフェン、フェブラゾン、ロキソプ
ロフェン、アンツェナフナトリウム、オキサプロジン、
エモルファゾン、チアプロフェン、フェンブフェン、プ
ラノプロフェン、フェンチアザツク、ジクロツェナフナ
トリウム、ジフルニサール、イブプロフェンピコノール
、ペンダザック、及びスプロフェン、並びにこれらのエ
ステル誘導体、あるいは塩酸ブプレノルフィン、ペンダ
ザック、酒石酸ブトルファノール等。The drugs contained are not particularly limited as long as they are transdermally absorbable drugs, such as salicylic acid, methyl salicylate, glycol salicylate, etc. as skin irritants and analgesic and anti-inflammatory agents.
- Menthol, camphor, pepper oil, thymol, nicotinic acid benzyl ester, capsicum extract, kabsaicin, nonylic acid vanillylamide, felbinac, butyl flufenamate, piroxicam, indomethacin, ketoprofen, pranoprofen, febrazone, loxoprofen, anzenaf sodium, oxaprozin,
Emorphazone, tiaprofen, fenbufen, pranoprofen, fentiazac, diclozenaf sodium, diflunisal, ibuprofenpiconol, pendazac, and suprofen, and their ester derivatives, or buprenorphine hydrochloride, pendazac, butorphanol tartrate, etc.
中枢神経作用剤(催眠鎮静剤、抗てんがん剤、精神神経
用剤)として、フルフェナジン、チオリダジン、ジアゼ
パム、クロルプロマジン、ニトラゼバム、エスタゾラム
、トリアゾラム、ニメタゼパム、フルジアゼパム、ハロ
キサゾラム、フルラゼパム、クロナゼパム、プロベリジ
アジン、プロクロルペラジン、アルブラシラム、オキサ
ゼパム、オキサゾラム、クロキサゾラム、プラゼパム、
フルタゾラム、メキサゾラム、ロラゼバム、フルジアゼ
パム、プロマゼパム、メタゼバム等。Central nervous system acting agents (hypnotic sedatives, anti-epileptic drugs, neuropsychiatric drugs) include fluphenazine, thioridazine, diazepam, chlorpromazine, nitrazebam, estazolam, triazolam, nimetazepam, fludiazepam, haloxazolam, flurazepam, clonazepam, proberidiazine, Prochlorperazine, Albrasulam, Oxazepam, Oxazolam, Cloxazolam, Prazepam,
Flutazolam, mexazolam, lorazebam, fludiazepam, promazepam, metazebam, etc.
利尿剤としてハイドロサイアザイド、ペンドロフルナサ
イアザイド、エチアジド、シクロペンチアジド、ヒドロ
クロロチアジド、ペンフルチド、メチクロチアジド、フ
ロセミド、メトラゾン2ポリチアジド、ペンドロフルメ
チアジド等。Diuretics include hydrothiazide, pendroflunathiazide, ethiazide, cyclopenthiazide, hydrochlorothiazide, penflutide, methyclothiazide, furosemide, metolazone 2 polythiazide, pendroflumethiazide, etc.
血圧降下剤としてクロニジン、アルサーオキシロン、レ
シナミン、メシル酸ジヒドロエルゴトキシン、レセルピ
ン、プラゾシン、カプトプリル、ピンドロール、マレイ
ン酸エナラプリル等。Antihypertensive agents include clonidine, altheroxiron, recinamine, dihydroergotoxin mesylate, reserpine, prazosin, captopril, pindolol, enalapril maleate, etc.
冠血管拡張剤としてニトログリセリン、ニトログリコー
ル、イソソルバイトシナイトレート、塩酸ババベリン、
ジピリダモール、エフロキサート、トリメタシン、ニコ
ランジル、シンナリジン、ナイリドン、モルシドミンニ
フエジピン等。Coronary vasodilators include nitroglycerin, nitroglycol, isosorbite cinitrate, bababerine hydrochloride,
Dipyridamole, efloxate, trimetacin, nicorandil, cinnarizine, nyridone, molsidomine nifedipine, etc.
鎮咳去痰剤としてリン酸コディン、リン酸ジヒドロコデ
ィン、塩酸エフェドリン、塩酸クロルプレナリン、臭化
水素酸フェノチロール、硫酸サルブタモール、リン酸ジ
メモルファン、塩酸アゼラスチン、塩酸クレンブテロー
ル、塩酸ツロブテロール、塩酸トリメトキノール、塩酸
プロカテロール、fJ[7’ロムヘキシン、トラニラス
ト、ヒベンズ酸チペピジン、フマル酸ケトチフエン、フ
マル酸フォルモチロール、リン酸ペンスブロベリン、グ
リチルレチン酸等。As an antitussive expectorant: codine phosphate, dihydrocodine phosphate, ephedrine hydrochloride, chlorprenaline hydrochloride, phenotyrol hydrobromide, salbutamol sulfate, dimemorphan phosphate, azelastine hydrochloride, clenbuterol hydrochloride, tulobuterol hydrochloride, trimetoquinol hydrochloride, hydrochloric acid Procaterol, fJ[7' romhexine, tranilast, tipepidine hibenzate, ketotifen fumarate, formotyol fumarate, pensbroverine phosphate, glycyrrhetinic acid, etc.
抗ヒスタミン剤として塩酸ジフェンヒドラミン、塩酸ト
リプロリジン、塩酸イソチベンジル、塩酸プロメタシン
、マレイン酸クロルフェニラミン、塩酸シブロヘブタジ
ン、フマル酸りレマスチン、マレイン酸カルビノキサミ
ン、マレイン酸ジメチンデン等。Antihistamines include diphenhydramine hydrochloride, triprolidine hydrochloride, isotibenzyl hydrochloride, promethacin hydrochloride, chlorpheniramine maleate, cibrohebutadine hydrochloride, lemastine fumarate, carbinoxamine maleate, dimethindene maleate, etc.
不整脈用剤としてアルプレノロール、オクスブレノロー
ル、ブクモロール、ブプラノロール、ピンドロール、イ
ンデノロール、カルテオロール、ブクモロール、プロプ
ラノロール、チモロール等。Antiarrhythmic agents include alprenolol, oxbrenolol, bucumolol, bupranolol, pindolol, indenolol, carteolol, bucumolol, propranolol, timolol, etc.
強心剤としてジキタリス、ユビデカレノン、ジゴキシン
、メチルジゴキシン、デスラノシド等。Cardiotropes include digitalis, ubidecarenone, digoxin, methyldigoxin, and deslanoside.
避妊薬としてエストラジオールエナンテート、エストラ
ジオールシビネート、レボノルゲストレル、エストラジ
オール等。Estradiol enanthate, estradiol cibinate, levonorgestrel, estradiol, etc. as contraceptives.
副腎皮質ホルモン剤として酢酸ヒドロコルチゾン、ヒド
ロコルチゾン、プレドニゾロン、トリアムシノロンアセ
トニド、デキサメタシンリン酸エステル、メチルプレド
ニゾロン、酢酸グイクロリシン、酢酸メチルプレドニゾ
ロン、フルオシノロンアセトニド、酢酸デキサメタシン
、デキサメタシン、フルオロメトロン、リン酸ベタメタ
シンナトリウム、ベタメタシン、吉草酸ベタメタシン、
プロピオン酸ベクロメタゾン、フルドロキシコルチド、
酪酸ヒドロコルチゾン、ジプロピオン酸ベタメタシン、
フルオシノニド、プロピオン酸クロベタプール、吉草酸
ジフルコルトロン、ハルジノニド、アムシノニド、吉草
酸プレドニゾロン等。Corticosteroids include hydrocortisone acetate, hydrocortisone, prednisolone, triamcinolone acetonide, dexamethacin phosphate, methylprednisolone, gyclorisine acetate, methylprednisolone acetate, fluocinolone acetonide, dexamethacin acetate, dexamethacin, fluorometholone, betametha phosphate cinsodium, betamethacin, betamethacin valerate,
Beclomethasone propionate, fludroxycortide,
Hydrocortisone butyrate, betamethacin dipropionate,
Fluocinonide, clobetapur propionate, diflucortolone valerate, haldinonide, amcinonide, prednisolone valerate, etc.
局所麻酔剤としてリドカイン、アミノ安息香酸エチル、
塩酸プロ力イン、ジブカイン、プロカイン等が挙げられ
る。lidocaine, ethyl aminobenzoate, as a local anesthetic;
Examples include procaine hydrochloride, dibucaine, and procaine.
これら薬効成分は、一種又は二種以上適宜配合されて用
いられる。These medicinal ingredients may be used alone or in combination of two or more.
又、救急絆創膏、手術後の傷口保護を目的としたサージ
カルドレッシング、切開部の細菌汚染防止を目的とした
サージカルドレープ、切開縫合部の補強固定用テープ、
更にはスポーツ時に用いるテーピング等にも利用可能で
ある。In addition, emergency bandages, surgical dressings to protect wounds after surgery, surgical drapes to prevent bacterial contamination of incisions, tapes for reinforcing and fixing incisions and sutures,
Furthermore, it can also be used for taping used during sports.
支持体としては、例えばポリエチレン、ポリプロピレン
、ポリブタジェン、エチレン酢酸ビニル共重合体、ポリ
塩化ビニル、ポリエステル、ナイロン、ポリウレタン等
のフィルム又はシート、あるいはこれらの多孔体、発泡
体そして紙、布、不織布等の伸縮性又は非伸縮性の支持
体より選ばれる。Examples of the support include films or sheets of polyethylene, polypropylene, polybutadiene, ethylene vinyl acetate copolymer, polyvinyl chloride, polyester, nylon, polyurethane, or porous bodies and foams thereof, as well as paper, cloth, nonwoven fabric, etc. Selected from stretchable or non-stretchable supports.
次に、製造法としては従来実施されている方法でも良い
が、−例として溶解あるいは混練された基剤成分に吸水
高分子を添加、均一に分散させ、更に必要に応じて薬効
成分等を添加、テープあるいはシート基材に直接展延す
るか、もしくはいったん剥離処理の施された紙、フィル
ム等に展延し、その後使用する基材に圧着転写して製造
することもできる。Next, the manufacturing method may be a conventional method, but for example, a water-absorbing polymer is added to the dissolved or kneaded base component and dispersed uniformly, and further medicinal ingredients are added as necessary. It can also be produced by directly spreading it on a tape or sheet substrate, or by first spreading it on a paper, film, etc. that has been subjected to a release treatment, and then pressure-transferring it onto the substrate to be used.
立貝四来
このようにして得られた本発明の貼付剤は、後述の試験
例、実施例で述べる如く、吸水高分子の配合が不可欠で
あり、基剤成分に配合されることにより、基剤中に配合
した吸水高分子が気触れの原因となる汗を吸収し、且つ
膏体のゲル的性質から体毛を巻き込むことがなく、剥離
時に毛を引っ張る等の物理的作用を及ぼさない、従って
貼付剤特有の生理的、物理的要因による気触れの原因を
排除しているものと推察される。また、接着力や凝集力
等の物性値の経時変化が小さいために初期の適度な粘着
感が長期間係たれ、従って接着力増加に起因する皮膚か
らの剥離時の発赤、かぶれなどが全く認められない。こ
の様な作用効果は、従来貼付剤に配合されている水溶性
高分子、多I!!1ガム等においては得られなかったも
のである。Shirai Tachikai In the patch of the present invention obtained in this way, as described in the test examples and examples below, it is essential to incorporate a water-absorbing polymer, and by incorporating it into the base component, the The water-absorbing polymer blended into the agent absorbs sweat, which causes irritation, and the gel-like nature of the paste does not involve body hair, and does not cause physical effects such as pulling hair when peeling off. It is presumed that the causes of discomfort caused by physiological and physical factors unique to patches are eliminated. In addition, because physical property values such as adhesive strength and cohesive strength change little over time, the initial moderate adhesive feeling remains for a long time, and therefore no redness or rash is observed when peeling off from the skin due to increased adhesive strength. I can't. These effects are due to the water-soluble polymer, Multi-I!, which is conventionally included in patches. ! 1 gum etc., which could not be obtained.
本発明による外用貼付剤は、 1)ムレ、発汗等による気触れの生理的因子の排除。The external patch according to the present invention includes: 1) Elimination of physiological factors such as stuffiness and sweating.
2)剥離時の毛の引っ張り等による気触れの物理的因子
の排除。2) Elimination of physical factors such as hair pulling during peeling.
と、従来の外用貼付剤では考えられなかった理想的な無
刺激性の外用貼付剤となる。This makes it an ideal non-irritating topical patch, which was unimaginable with conventional topical patches.
上述の作用及び効果を実施例及び試験例により、更に詳
しく説明する。The above-mentioned functions and effects will be explained in more detail with reference to Examples and Test Examples.
実施例1
スチレン−イソプレン−スチレンブロック共重合体カリ
フレックスTR−1107(シェル化学型)22重量部
、アルコン−Ploo (荒川化学製)40重量部、流
動パラフィン20重量部よりなる基剤成分にアラソーブ
800F (荒川化学製)10重量部を添加混合、つい
でサリチル酸メチル3重量部、l−メントール3重量部
、a−カンフル2重量部を配合し、ポリエステルナイロ
ン基布に厚さ100μmになるように展延、シリコーン
処理の施されたポリプロピレンフィルムで覆い所望の形
に切断し、本発明の無刺激性貼付剤とした。Example 1 Arasorb was added to a base component consisting of 22 parts by weight of styrene-isoprene-styrene block copolymer Cariflex TR-1107 (shell chemical type), 40 parts by weight of Alcon-Ploo (manufactured by Arakawa Chemical), and 20 parts by weight of liquid paraffin. 800F (manufactured by Arakawa Chemical) was added and mixed, and then 3 parts by weight of methyl salicylate, 3 parts by weight of l-menthol, and 2 parts by weight of a-camphor were added and spread on a polyester nylon base fabric to a thickness of 100 μm. The mixture was rolled and covered with a silicone-treated polypropylene film and cut into a desired shape to obtain a non-irritating adhesive patch of the present invention.
本貼付剤を貼付したところ、良好な清涼感が持続し、剥
離時における毛の引っ張りもなく、剥離後の発赤、気触
れ等は皆無であった。When this adhesive patch was applied, a good cooling sensation persisted, there was no hair pulling during removal, and there was no redness or discomfort after removal.
実施例2
スチレン−イソプレン−スチレンブロック共重合体カリ
フレックスTR−1107(シェル化学型)30重量部
、YSレジン(安原油脂製)35重量部、流動パラフィ
ン13重量部よりなる基剤成分にサンウェフトIM−1
000MPS (三洋化成製)12重量部を添加混合、
ついでサリチル酸メチル6重量部、!−メントール3重
量部、a−カンフル1重量部を配合し、シリコーン処理
の施された剥離紙に厚さ150μmになるように展延し
た後、塩化ビニルフィルムをかぶせ圧着転写し、所望の
形に切断、本発明の貼付剤とした。Example 2 Sunweft IM was added to the base component consisting of 30 parts by weight of styrene-isoprene-styrene block copolymer Cariflex TR-1107 (Shell chemical type), 35 parts by weight of YS resin (Yasu Oil Co., Ltd.), and 13 parts by weight of liquid paraffin. -1
Add and mix 12 parts by weight of 000MPS (manufactured by Sanyo Chemical),
Next, 6 parts by weight of methyl salicylate! - Mix 3 parts by weight of menthol and 1 part by weight of a-camphor, spread on silicone-treated release paper to a thickness of 150 μm, cover with vinyl chloride film, press and transfer, and form into the desired shape. The sample was cut into a patch of the present invention.
本貼付剤を貼付したところ、実施例1と同様の効果を示
した。When this patch was applied, it showed the same effect as in Example 1.
実施例3
スチレン−イソプレン−スチレンブロック共重合体ツル
プレン−418(フィリップスベトロリアム製)29重
量部、レガレフッ(パーキュリーズ製)35重量部、流
動パラフィン15重量部よりなる基剤成分に、スミカゲ
ルNP−1020(住友化学製)10重量部を添加混合
、ついでサリチル酸メチル5重量部、!−メントール4
重量部、a−カンフル2重量部を配合し、不透過処理の
施された不織布に厚さ200μmになるように展延した
後、シリコーン処理の施されたPETフィルムで覆い、
所望の形に切断、本発明の貼付剤とした。Example 3 A base component consisting of 29 parts by weight of styrene-isoprene-styrene block copolymer Turprene-418 (manufactured by Philips Vetroleum), 35 parts by weight of Regare Fluid (manufactured by Percules), and 15 parts by weight of liquid paraffin was added with Sumikagel NP- Add and mix 10 parts by weight of 1020 (manufactured by Sumitomo Chemical), then 5 parts by weight of methyl salicylate,! -Menthol 4
parts by weight and 2 parts by weight of a-camphor, spread on a non-woven fabric treated with impermeability to a thickness of 200 μm, and then covered with a PET film treated with silicone.
It was cut into a desired shape to prepare the adhesive patch of the present invention.
本貼付剤を貼付したところ、実施例1と同様の効果を示
した。When this patch was applied, it showed the same effect as in Example 1.
実施例4
天然ゴム27重量部、ポリブテン15重量部、ハリニス
ター(播磨化成製)27重量部、炭酸カルシウム14重
量部よりなる基剤成分に、アラソーブ800F (荒川
化学製)2重量部を添加混合、ついでサリチル酸メチル
8重量部、l−メントール6重量部、d−カンフル1重
量部を配合し、不織布に厚さ200μmになるように展
延した後、シリコーン処理の施された剥離紙をかぶせ、
所望の形に切断、本発明の外用貼付剤とした。Example 4 2 parts by weight of Arasorb 800F (manufactured by Arakawa Chemical Co., Ltd.) was added and mixed to a base component consisting of 27 parts by weight of natural rubber, 15 parts by weight of polybutene, 27 parts by weight of Harinister (manufactured by Harima Kasei), and 14 parts by weight of calcium carbonate. Next, 8 parts by weight of methyl salicylate, 6 parts by weight of l-menthol, and 1 part by weight of d-camphor were blended, spread on a nonwoven fabric to a thickness of 200 μm, and covered with release paper treated with silicone.
It was cut into a desired shape to prepare the external patch of the present invention.
本貼付剤を貼付したところ、実施例1と同様の効果を示
した。When this patch was applied, it showed the same effect as in Example 1.
実施例5
アクリル酸エステル共重合体バインゾールR−35(一
方社油脂工業製)75重量部、グリセリン2重量部より
なる基剤成分に、スミカゲルNP−1040(住人化学
製)20重量部を添加混合、ついでインドメタシン3重
量部を配合し、シリコーン処理の施された剥離紙に厚さ
100μmになるように展延した後、ポリエチレンフィ
ルムをかぶせ、圧着転写し、所望の形に切断、本発明の
貼付剤とした。Example 5 20 parts by weight of Sumikagel NP-1040 (manufactured by Sumika Gel) was added and mixed to a base component consisting of 75 parts by weight of acrylic acid ester copolymer Binsol R-35 (manufactured by Ipposha Yushi Kogyo) and 2 parts by weight of glycerin. Then, 3 parts by weight of indomethacin was added, spread on a silicone-treated release paper to a thickness of 100 μm, covered with a polyethylene film, pressure-transferred, cut into a desired shape, and applied according to the present invention. It was used as a drug.
本貼付剤を貼付したところ、実施例1と同様の効果を示
した。When this patch was applied, it showed the same effect as in Example 1.
実施例6
スチレン−イソブレン−スチレン共重合体カリフレック
スTR−1111(シェル化学型)27重量部、エステ
ルガム(荒用化学製)28重量部、流動パラフィン20
重量部よりなる基剤成分に、サンウェットIM−100
0MPS (三洋化成製)20重量部を添加混合、つい
でクロニジン5重量部を配合し、シリコーン処理の施さ
れたPETフィルムに厚さ120μmになるように展延
した後、ナイロンフィルムで覆い、圧着転写し、所望の
形に切断、本発明の貼付剤とした。Example 6 Styrene-isobrene-styrene copolymer Cariflex TR-1111 (shell chemical type) 27 parts by weight, ester gum (Arayo Kagaku) 28 parts by weight, liquid paraffin 20
Sanwet IM-100 is added to the base component consisting of parts by weight.
Add and mix 20 parts by weight of 0MPS (manufactured by Sanyo Kasei), then 5 parts by weight of clonidine, spread it on a silicone-treated PET film to a thickness of 120 μm, cover it with a nylon film, and press transfer. Then, it was cut into a desired shape to obtain the adhesive patch of the present invention.
本貼付剤を貼付したところ、実施例1と同様の効果を示
した。When this patch was applied, it showed the same effect as in Example 1.
実施例7
アクリル酸エステル共重合体二カゾールTS−444(
日本カーバイド工業製)85重量部、1゜3ブチレング
リコ一ル6重量部よりなる基剤成分に、アクアキープ4
SH(製鉄化学製)5重量部を添加混合、ついでケトプ
ロフェン4重量部を配合し、シリコーン処理の施された
PETフィルムに厚さ150μmになるように展延した
後、ポリエチレンフィルムをかぶせ、圧着転写し、所望
の形に切断、本発明の貼付剤とした。Example 7 Acrylic acid ester copolymer dicazole TS-444 (
Aqua Keep 4 was added to the base component consisting of 85 parts by weight (manufactured by Nippon Carbide Kogyo) and 6 parts by weight of 1゜3 butylene glycol.
Add and mix 5 parts by weight of SH (manufactured by Seitetsu Kagaku), then 4 parts by weight of ketoprofen, spread on a silicone-treated PET film to a thickness of 150 μm, cover with a polyethylene film, and press transfer. Then, it was cut into a desired shape to obtain the adhesive patch of the present invention.
本貼付剤を貼付したところ、実施例1と同様の効果を示
した。When this patch was applied, it showed the same effect as in Example 1.
実施例8
天然ゴム22重量部、ポリブテン17重量部、エスコレ
ソツ(エクソン製)3 (N11g(S、酸化亜鉛20
重量部よりなる基剤成分に、サンウェフトIM−300
MPS (三洋化成製)3重量部を添加混合、ついでサ
リチル酸メチル3重量部、サリチル酸グリコール2重量
部、l−メントール2重量部、a−カンフル1重量部を
配合し、布に厚さ200μmになるように展延した後、
シリコーン処理の施された剥離紙をかぶせ、所望の形に
切断、本発明の外用貼付剤とした。Example 8 22 parts by weight of natural rubber, 17 parts by weight of polybutene, 3 parts by weight of Escoresotu (manufactured by Exxon) (11 g of N (S, 20 parts of zinc oxide)
The base component consists of parts by weight of Sunweft IM-300.
Add and mix 3 parts by weight of MPS (manufactured by Sanyo Kasei), then add 3 parts by weight of methyl salicylate, 2 parts by weight of glycol salicylate, 2 parts by weight of l-menthol, and 1 part by weight of a-camphor to form a cloth with a thickness of 200 μm. After spreading like this,
It was covered with silicone-treated release paper and cut into a desired shape to obtain the external patch of the present invention.
本貼付剤を貼付したところ、実施例1と同様の効果を示
した。When this patch was applied, it showed the same effect as in Example 1.
実施例9
スチレン−イソプレン−スチレン共重合体カリフレック
スTR−1107(シェル化学型)32重量部、ハリタ
ック(播磨化成製)40重量部、流動パラフィン15重
量部よりなる基剤成分に、アラソーブ800F (荒用
化学製)12重量部を添加混合、ついでケトチフエン1
重量部を配合し、シリコーン処理の施されたPETフィ
ルムに厚さ50μmになるように展延した後、ポリプロ
ピレンシートをかぶせ、圧着転写し、所望の形に切断、
本発明の貼付剤とした。Example 9 Arasorb 800F ( Add and mix 12 parts by weight (manufactured by Arayo Kagaku), then 1 part of ketothiphen
After blending parts by weight and spreading it to a thickness of 50 μm on a silicone-treated PET film, cover with a polypropylene sheet, press and transfer, cut into desired shape,
A patch of the present invention was prepared.
本貼付剤を貼付したところ、実施例1と同様の効果を示
した。When this patch was applied, it showed the same effect as in Example 1.
実施例10
スチレン−イソプレン−スチレン共重合体カリフレック
スTR−1107(シェル化学型)26重量部、ポリイ
ソブチレン(エクソン化学型)10重量部、ピコライト
(パーキュリーズ製)32重量部、流動パラフィン20
重量部よりなる基剤成分に、アクアキープ4S(製鉄化
学製)9重量部を添加混合、ついでピンドロール3重量
部を配合し、シリコーン処理の施されたPETフィルム
に厚さ150μmになるように展延した後、ボリ塩化ビ
ニルフィルムをかぶせ、圧着転写し、所望の形に切断、
本発明の貼付剤とした。Example 10 Styrene-isoprene-styrene copolymer Cauliflex TR-1107 (Shell chemical type) 26 parts by weight, polyisobutylene (Exxon chemical type) 10 parts by weight, Picolite (Percules) 32 parts by weight, liquid paraffin 20 parts by weight
9 parts by weight of Aqua Keep 4S (manufactured by Seitetsu Kagaku Co., Ltd.) was added and mixed into the base component consisting of parts by weight, and then 3 parts by weight of Pindolol was added and spread on a silicone-treated PET film to a thickness of 150 μm. After rolling out, cover with polyvinyl chloride film, press and transfer, cut into desired shape,
A patch of the present invention was prepared.
本貼付剤を貼付したところ、実施例1と同様の効果を示
した。When this patch was applied, it showed the same effect as in Example 1.
実施例11
天然ゴム35重量部、ポリブテン10重量部、ysレジ
ン(安原油脂製)27重量部、酸化亜鉛16重量部より
なる基剤成分に、アラソープ800F(荒用化学製)を
微粉化したちの1.5重量部を添加混合、ついでサリチ
ル酸メチル5重量部、!−メントール4重量部、a−カ
ンフル1.5重量部を配合し、布に厚さ200μmにな
るように展延した後、シリコーン処理の施された剥離紙
をかぶせ、所望の形に切断、本発明の貼付剤とした。Example 11 Arasoap 800F (manufactured by Arayo Chemical Co., Ltd.) was pulverized into a base component consisting of 35 parts by weight of natural rubber, 10 parts by weight of polybutene, 27 parts by weight of ys resin (manufactured by Cheap Oil Co., Ltd.), and 16 parts by weight of zinc oxide. Add 1.5 parts by weight and mix, then 5 parts by weight of methyl salicylate! - Mix 4 parts by weight of menthol and 1.5 parts by weight of a-camphor, spread on cloth to a thickness of 200 μm, cover with silicone-treated release paper, cut into desired shape, and book. The invention was made into a patch.
本貼付剤を貼付したところ、実施例1と同等またはそれ
以上の効果を示した。When this patch was applied, it showed an effect equal to or better than that of Example 1.
実施例12
天然ゴム15重量部、ポリイソブチレン25重量部、液
状インプレンゴム10重量部、アルコンP−100(荒
用化学製)20.5重量部、含水シリカ15重量部より
なる基剤成分に、サンウェットIM−1000MPS
(三洋化成製)2重量部を添加混合、ついでサリチル酸
メチル8重量部、!−メントール3重量部、〃−カンフ
ル1.5重量部を配合し、布に200μmになるように
展延した後、シリコーン処理した剥離紙をかぶせ、所望
の形に切断、本発明の貼付剤とした。Example 12 A base component consisting of 15 parts by weight of natural rubber, 25 parts by weight of polyisobutylene, 10 parts by weight of liquid impregnated rubber, 20.5 parts by weight of Alcon P-100 (manufactured by Arayo Kagaku), and 15 parts by weight of hydrated silica, Sunwet IM-1000MPS
(manufactured by Sanyo Chemical) 2 parts by weight were added and mixed, then 8 parts by weight of methyl salicylate,! - 3 parts by weight of menthol and 1.5 parts by weight of camphor were blended and spread on cloth to a thickness of 200 μm, covered with silicone-treated release paper and cut into the desired shape. did.
本貼付剤を貼付したところ、実施例1と同等またはそれ
以上の効果を示した。When this patch was applied, it showed an effect equal to or better than that of Example 1.
実施例13
天然ゴム40重量部、流動パラフィン5重量部、エステ
ルガム(荒用化学製)28重量部、含水シリカ8重量部
からなる基剤成分に、あらかじめ酸化亜鉛7重量部にア
ラソープ800Fを微粉化したちの0.5重量部とサン
ウェットIM−1000MPS (三洋化成製)0.5
重量部を混合したものを添加混合し、ついでサリチル酸
メチル8重量部、!−メントール3重量部を配合し、布
に厚さ200μmになるように展延した後、シリコーン
処理した剥離紙をかぶせ、所望の形に切断、本発明の貼
付剤とした。Example 13 To a base component consisting of 40 parts by weight of natural rubber, 5 parts by weight of liquid paraffin, 28 parts by weight of ester gum (manufactured by Arayo Kagaku), and 8 parts by weight of hydrated silica, 7 parts by weight of zinc oxide and fine powder of Arasop 800F were added in advance. 0.5 parts by weight of Kashitachi and 0.5 parts of Sunwet IM-1000MPS (manufactured by Sanyo Chemical)
Add and mix 8 parts by weight of methyl salicylate, and then 8 parts by weight of methyl salicylate! - 3 parts by weight of menthol was blended and spread on cloth to a thickness of 200 μm, covered with silicone-treated release paper, and cut into a desired shape to obtain the patch of the present invention.
本貼付剤を貼付したところ、実施例1と同等またはそれ
以上の効果を示した。When this patch was applied, it showed an effect equal to or better than that of Example 1.
実施例14
天然ゴム30重量部、ポリイソブチ1710重量部、流
動パラフィン7.5重量部、エステルガム(荒用化学製
)27.5重量部、含水シリカ10重量部からなる基剤
成分に、あらかじめ酸化亜鉛5重量部にアラソープFを
微粉化したちの0.95重量部とヒアルロンサンHA−
3(キエービ製)0.05重量部を混合したものを添加
混合し、ついでサリチル酸メチル6重量部、!−メント
ール2重量部、〃−カンフル1重量部を配合し、布に厚
さ200μmになるように展延した後シリコーン処理し
た剥離紙をかぶせ、所望の形に切断、本発明の貼付剤と
した。Example 14 A base component consisting of 30 parts by weight of natural rubber, 1710 parts by weight of polyisobutylene, 7.5 parts by weight of liquid paraffin, 27.5 parts by weight of ester gum (manufactured by Arayo Kagaku), and 10 parts by weight of hydrated silica was oxidized in advance. 5 parts by weight of zinc, 0.95 parts by weight of finely powdered Arasorp F, and Hyaluronic Sun HA-
3 (manufactured by Kievi) 0.05 parts by weight was added and mixed, then 6 parts by weight of methyl salicylate,! -2 parts by weight of menthol and 1 part by weight of camphor were blended, spread on cloth to a thickness of 200 μm, covered with silicone-treated release paper, and cut into the desired shape to obtain the patch of the present invention. .
実施例15
天然ゴム20重量部、ポリイソブチレン20重量部、液
状ポリイソプレン5重量部、アルコンP−100(荒用
化学製)30重量部、酸化亜鉛20重量部からなる基剤
成分に、バイオヒアルロン酸ナトリウム(資生堂製)1
重量部を添加混合、ついでケトプロフェン4重量部を配
合し、布に厚さ200μmになるように展延した後、シ
リコーン処理した剥離紙をかぶせ、所望の形に切断、本
発明の貼付剤とした。Example 15 Biohyaluron was added to a base component consisting of 20 parts by weight of natural rubber, 20 parts by weight of polyisobutylene, 5 parts by weight of liquid polyisoprene, 30 parts by weight of Alcon P-100 (manufactured by Arayo Kagaku), and 20 parts by weight of zinc oxide. Sodium acid (manufactured by Shiseido) 1
Then, 4 parts by weight of ketoprofen was added and mixed, and the mixture was spread on cloth to a thickness of 200 μm, covered with silicone-treated release paper, and cut into a desired shape to obtain the patch of the present invention. .
本貼付剤を貼付したところ、実施例1と同等なまたはそ
れ以上の効果を示した。When this patch was applied, it showed an effect equivalent to or better than that of Example 1.
実施例16
スチレン−イソプレン−スチレンブロック共重合体カリ
フレックスTR−1111(シェル化学型)15重量部
、ビスタネックスMML−100(エッソスタンダード
石油製)3重量部、ビスタネックスLM−MH8重量部
、流動パラフィン30重量部、水添ロジンエステル(荒
用化学製)15重量部よりなる基剤成分に、サンウェッ
トIM−300MPS (三洋化成製)10重量部、ポ
リビニルアルコールS M R−10t、 ((KM化
学製)7重量部を添加混合、次にサリチル酸グリコール
5重量部、!−メントール7重量部を配合し、剥離紙に
厚さ200μmになるように展延、不織布に転写し、所
望の形に切断、本発明の貼付剤とした。Example 16 Styrene-isoprene-styrene block copolymer Cauliflex TR-1111 (shell chemical type) 15 parts by weight, Vistanex MML-100 (Esso Standard Oil Co., Ltd.) 3 parts by weight, Vistanex LM-MH 8 parts by weight, fluid A base component consisting of 30 parts by weight of paraffin, 15 parts by weight of hydrogenated rosin ester (manufactured by Arayo Kagaku), 10 parts by weight of Sunwet IM-300MPS (manufactured by Sanyo Kasei), polyvinyl alcohol S M R-10t, ((KM 7 parts by weight of glycol salicylate and 7 parts by weight of !-menthol were added and mixed, spread on release paper to a thickness of 200 μm, transferred to non-woven fabric, and shaped into the desired shape. The sample was cut into a patch of the present invention.
本貼付剤を貼付したところ、実施例1と同様の効果を示
した。When this patch was applied, it showed the same effect as in Example 1.
実施例17
スチレン−イソブレン−スチレンブロック共重合体ツル
ブレン−418(フィリンブスペトロリアム製)20重
量部、ビスタネソクスLM−MH(エッソスタンダード
石油製)5重量部、ポリブテン31i量部、クラプレン
LIR−30(クラレ製)25重量部、アルコンp−t
ooc荒用化学製)30重量部よりなる基剤成分に、ア
ラソーブ800F (荒用化学製)6重量部、アルコッ
クスE−30(明成化学工業製)3重量部を添加混合、
次にサリチル酸メチル5重量部、E−メントール2.5
重量部、トウガランエキス0.5重量部を配合し、不織
布に厚さ150μmになるように展延した後、シリコー
ン処理を施されたポリエステルフィルムで覆い、所望の
形に切断、本発明の貼付剤とした。Example 17 Styrene-isobrene-styrene block copolymer Trublene-418 (manufactured by Philimbus Petroleum) 20 parts by weight, Vistanesox LM-MH (Esso Standard Sekiyu) 5 parts by weight, polybutene 31i parts, Claprene LIR-30 (Kuraray) ) 25 parts by weight, Alcon PT
6 parts by weight of Arasorb 800F (manufactured by Arayo Kagaku) and 3 parts by weight of Alcox E-30 (manufactured by Meisei Kagaku Kogyo) were added and mixed to a base component consisting of 30 parts by weight of OOC (manufactured by Arayo Kagaku),
Next, 5 parts by weight of methyl salicylate, 2.5 parts of E-menthol
part by weight, and 0.5 part by weight of chili pepper extract, spread it on a nonwoven fabric to a thickness of 150 μm, cover it with a silicone-treated polyester film, cut it into a desired shape, and apply the present invention. It was used as a drug.
、本貼付剤を貼付したところ、実施例1と同様の効果を
示した。When this patch was applied, it showed the same effect as in Example 1.
実施例18
スチレン−イソプレン−スチレンブロック共重合体カリ
フレックスTR−1107(シェル化学型)25重量部
、ビスタネックスLM−MH(エッソスタンダード製)
10重量部、流動パラフィン25重量部、水添ロジンエ
ステル(荒用化学製)18重量部よりなる基剤成分に、
スミカゲルNP−1020(住友化学製)3重量部、ソ
アレソクスBH(日本合成化学型)7重量部を添加混合
、次にサリチル酸グリコール5重量部、!−メントール
7重量部、ノニル酸ワニリルアミド0.01重量部を配
合し、剥離紙に厚さ100μmになるよう展延した後、
PvCシートで覆い転写し、所望の形に切断、本発明の
貼付剤とした。Example 18 Styrene-isoprene-styrene block copolymer Cauliflex TR-1107 (shell chemical type) 25 parts by weight, Vistanex LM-MH (manufactured by Esso Standard)
A base component consisting of 10 parts by weight, 25 parts by weight of liquid paraffin, and 18 parts by weight of hydrogenated rosin ester (manufactured by Arayo Kagaku),
Add and mix 3 parts by weight of Sumikagel NP-1020 (manufactured by Sumitomo Chemical) and 7 parts by weight of Soaresox BH (Nippon Gosei Chemical), then 5 parts by weight of glycol salicylate,! - After blending 7 parts by weight of menthol and 0.01 part by weight of nonylic acid vanillylamide and spreading it on release paper to a thickness of 100 μm,
The patch was covered with a PvC sheet, transferred, and cut into a desired shape to obtain the adhesive patch of the present invention.
本貼付剤を貼付したところ、実施例1と同様の効果を示
した。When this patch was applied, it showed the same effect as in Example 1.
実施例19
スチレン−イソプレン−スチレンブロック共重合体カリ
フレックスTR−1112(シェル化学m)25重1部
、スチレン−エチレン−ブチレン−スチレンブロック共
重合体クレイトン01657(シェル化学型)4重量部
、ポリブテン5重量部、流動パラフィン15重量部、水
添ロジンエステル(荒用化学製)25重量部、YSレジ
ンpx1000 (安原油脂工業製)5重量部よりなる
基剤成分にサンウェットIM−300MPS (三洋化
成製)10重量部、アルコックスE−30(明成化学工
業製)5重量部を添加混合、次にハツカ油3重量部、ケ
トプロフェン3重量部を配合し、シリコーン処理の施さ
れたポリエステルフィルムに厚さ100μmになるよう
展延した後、ポリエチレンフィルムで覆い、転写し、所
望の形に切断、本発明の貼付剤とした。Example 19 Styrene-isoprene-styrene block copolymer Cauliflex TR-1112 (Shell Chemical M) 25 parts by weight, styrene-ethylene-butylene-styrene block copolymer Kraton 01657 (Shell Chemical Type) 4 parts by weight, polybutene 5 parts by weight of liquid paraffin, 25 parts by weight of hydrogenated rosin ester (manufactured by Arayo Kagaku Co., Ltd.), and 5 parts by weight of YS Resin px1000 (manufactured by Yasushi Kogyo Co., Ltd.). 10 parts by weight of Alcox E-30 (manufactured by Meisei Chemical Industry Co., Ltd.) and 5 parts by weight of Alcox E-30 (manufactured by Meisei Chemical Industry Co., Ltd.) were added and mixed. Next, 3 parts by weight of peppermint oil and 3 parts by weight of ketoprofen were added to the silicone-treated polyester film. After spreading it to a thickness of 100 μm, it was covered with a polyethylene film, transferred, and cut into a desired shape to obtain the adhesive patch of the present invention.
本貼付剤を貼付したところ、実施例1と同様の効果を示
した。When this patch was applied, it showed the same effect as in Example 1.
実施例20
シリコーン355 (ダウコーニング社製)固型分90
重量部に対してサンウェットIM−1000MPS (
三洋化成製)3重量部を添加混合、ついでクロニジン7
重量部を添加混合し、PETフィルムに乾燥後の膜厚が
50μmになるように展延し、本発明の外用貼付剤とし
た。Example 20 Silicone 355 (manufactured by Dow Corning) Solid content 90
Sunwet IM-1000MPS (by weight)
Sanyo Chemical Co., Ltd.) 3 parts by weight were added and mixed, then clonidine 7
Parts by weight were added and mixed and spread on a PET film so that the film thickness after drying was 50 μm to obtain an external patch of the present invention.
実施例21
シリコーン355 (ダウコーニング社製)固型分92
重量部に対してスミカゲルNP−1020(住友化学製
)5重量部を添加混合し、ついでジクロフェナックナト
リウムを3重量部添加混合し、、ポリエチレンフィルム
に乾燥後の膜厚が75μmになるように展延し、本発明
の外用貼付剤とした。Example 21 Silicone 355 (manufactured by Dow Corning) Solid content 92
Add and mix 5 parts by weight of Sumikagel NP-1020 (manufactured by Sumitomo Chemical) to the parts by weight, then add and mix 3 parts by weight of diclofenac sodium, and spread on a polyethylene film so that the film thickness after drying is 75 μm. This was used as an external patch of the present invention.
実施例22
シリコーン4−4210(ダウコーニング社製)85重
量部とKIゲル−201に−F2 (クラレ製)5重量
部を添加し、ついで!−メントール3.5重量部とサリ
チル酸グリコール3.5重量部とを添加混合し、その後
架橋剤3重量部を添加し、ポリエチレンフィルムに11
00pの厚さになるように展延し、本発明の外用貼付剤
とした。Example 22 5 parts by weight of -F2 (manufactured by Kuraray) were added to 85 parts by weight of Silicone 4-4210 (manufactured by Dow Corning) and KI Gel-201, and then! - Add and mix 3.5 parts by weight of menthol and 3.5 parts by weight of glycol salicylate, then add 3 parts by weight of a crosslinking agent, and apply 11 parts by weight to a polyethylene film.
It was spread to a thickness of 00p to obtain the external patch of the present invention.
実施例23
シリコーン4−4210 (ダウコーニング社製)77
重量部にアラソーブ800F (荒用化学製)6重量部
を添加混合し、ついで流動パラフィン7重量部とクロニ
ジン6重量部を添加混合し、さらに架橋剤4重量部を混
合、PETフィルムに100μmの膜厚になるように展
延し、本発明の外用貼付剤とした。Example 23 Silicone 4-4210 (manufactured by Dow Corning) 77
Add and mix 6 parts by weight of Arasorb 800F (manufactured by Arayo Kagaku) to the parts by weight, then add and mix 7 parts by weight of liquid paraffin and 6 parts by weight of clonidine, and further mix 4 parts by weight of a crosslinking agent. It was spread to a thick layer to form the external patch of the present invention.
参考例1
スチレン−イソプレン−スチレンブロック共重合体カリ
フレックスTR−1107(シェル化学型)22重量部
、アルコン−Ploo (荒用化学製)40重量部、流
動パラフィン20重量部よりなる基剤成分に、ポリビニ
ルアルコール10ii量部を添加混合、ついでサリチル
酸メチル3重量部、l−メントール3重量部、d−カン
フル2重量部を配合し、ポリエステルナイロン基布に厚
さ100μmになるように展延、シリコーン処理の施さ
れたポリプロピレンフィルムで覆い、所望の形に切断し
、外用貼付剤とした。Reference Example 1 A base component consisting of 22 parts by weight of styrene-isoprene-styrene block copolymer Kaliflex TR-1107 (shell chemical type), 40 parts by weight of Alcon-Ploo (manufactured by Arayo Kagaku), and 20 parts by weight of liquid paraffin. , 10 parts by weight of polyvinyl alcohol were added and mixed, then 3 parts by weight of methyl salicylate, 3 parts by weight of l-menthol, and 2 parts by weight of d-camphor were added and spread on a polyester nylon base fabric to a thickness of 100 μm. It was covered with a treated polypropylene film and cut into a desired shape to prepare an external patch.
参考例2
スチレン−イソプレン−スチレンブロック共重合体カリ
フレックスTR−1107(シェル化学型)30重量部
、YSレジン(安原油脂製)35重量部、流動パラフィ
ン13重量部よりなる基剤成分に、ヒドロキシプロピル
セルロース12重量部を添加混合、ついでサリチル酸メ
チル6重量部、l−メントール3重量部、−一カンフル
1重量部を配合し、シリコーン処理の施された剥離紙に
厚さ150μmになるように展延した後、塩化ビニルフ
ィルムをかぶせ、圧着転写し、所望の形に切断、外用貼
付剤とした。Reference Example 2 A base component consisting of 30 parts by weight of styrene-isoprene-styrene block copolymer Cariflex TR-1107 (Shell chemical type), 35 parts by weight of YS resin (Yasu Oil Co., Ltd.), and 13 parts by weight of liquid paraffin was added with hydroxyl. Add and mix 12 parts by weight of propylcellulose, then mix 6 parts by weight of methyl salicylate, 3 parts by weight of l-menthol, and 1 part by weight of -1-camphor, and spread on silicone-treated release paper to a thickness of 150 μm. After spreading, it was covered with a vinyl chloride film, pressure-transferred, and cut into a desired shape to prepare an external patch.
参考例3
天然ゴム27重量部、ポリブテン15重量部、ハリニス
ター(播磨化成製)27重量部、炭酸カルシウム14重
量部よりなる基剤成分に、アラビアガム2重量部を添加
混合、ついでサリチル酸メチル8重量部、!−メントー
ル6重量部、a−カンフル1重量部を配合し、不織布に
厚さ200μmになるように展延した後、シリコーン処
理の施された剥離紙をかぶせ、所望の形に切断、外用貼
付剤とした。Reference Example 3 Add and mix 2 parts by weight of gum arabic to a base component consisting of 27 parts by weight of natural rubber, 15 parts by weight of polybutene, 27 parts by weight of Harinister (manufactured by Harima Kasei), and 14 parts by weight of calcium carbonate, and then 8 parts by weight of methyl salicylate. Department! - Blend 6 parts by weight of menthol and 1 part by weight of a-camphor, spread on a nonwoven fabric to a thickness of 200 μm, cover with silicone-treated release paper, cut into desired shape, and prepare an external patch. And so.
参考例4
天然ゴム30重量部、ポリブテン5重量部、YSレジン
(安原油脂製)18.5重量部、酸化亜鉛7重量部より
なる基剤成分に、アラソーブ800F(荒用化学製)3
0重量部添加混合、ついでサリチル酸メチル5重量部、
l−メントール3重量部、a−カンフル1.5重量部を
配合し、布に厚さ200μmになるように展延した後、
シリコーン処理された剥離紙をかぶせ、所望の形に切断
、外用貼付剤とした。Reference Example 4 Arasorb 800F (manufactured by Arayo Chemical Co., Ltd.) 3 was added to a base component consisting of 30 parts by weight of natural rubber, 5 parts by weight of polybutene, 18.5 parts by weight of YS resin (manufactured by Chesai Oil Co., Ltd.), and 7 parts by weight of zinc oxide.
0 parts by weight added and mixed, then 5 parts by weight of methyl salicylate,
After blending 3 parts by weight of l-menthol and 1.5 parts by weight of a-camphor and spreading it on cloth to a thickness of 200 μm,
It was covered with silicone-treated release paper and cut into a desired shape to prepare an external patch.
参考例5
天然ゴム40重量部、流動パラフィン5重量部、アルコ
ン(荒用化学製)27重量部、含水シリカ15重量部よ
りなる基剤成分に、サンウェット!M−300MPS
(三洋化成製)0.5重量部を添加混合、ついでサリチ
ル酸メチル8重量部、1−メントール3重量部、〃−カ
ンフル1.5重量部を配合し、布に厚さ200μmにな
るように展延した後、シリコーン処理の施された剥離紙
をかぶせ所望の形に切断、外用貼付剤とした。Reference Example 5 Sunwet! M-300MPS
Add and mix 0.5 parts by weight (manufactured by Sanyo Kasei), then 8 parts by weight of methyl salicylate, 3 parts by weight of 1-menthol, and 1.5 parts by weight of camphor, and spread it on a cloth to a thickness of 200 μm. After spreading, it was covered with silicone-treated release paper and cut into a desired shape to prepare an external patch.
試験例1 皮膚刺激試験
30名の被験者に本発明の実施例1〜5、実施例11〜
19及び参考例1〜3、比較例として市販の消炎鎮痛プ
ラスターA、の18種を用いて背部に48時間貼付、剥
離後1時間及び24時間経過後の皮膚変化を観察し、皮
膚刺激度を判定した。Test Example 1 Skin irritation test Examples 1 to 5 and Examples 11 to 30 of the present invention were administered to 30 subjects.
19 and Reference Examples 1 to 3, and commercially available anti-inflammatory and analgesic plaster A as a comparative example, 18 types were applied to the back for 48 hours, skin changes were observed 1 hour and 24 hours after peeling, and the degree of skin irritation was evaluated. I judged it.
その結果を表1に示す。The results are shown in Table 1.
(皮膚刺激判定基準は下記の通りである。)変化なし
; −
微弱な発赤 ; ±
明瞭な発赤 ; +
重篤な気触 ;++
表1
試験例2 吸水力比較試験
試験方法;
各被験サンプル5X6C1lのものを水中に浸瞳1時間
後に取り出しその重量を測定し、増加した重量を元の重
量で除し、吸水した量を表2に示す。(The criteria for determining skin irritation are as follows.) No change.
- Slight redness; ± Obvious redness; + Severe sensation; ++ Table 1 Test Example 2 Water Absorption Comparison Test Test Method; Each test sample (5 x 6 C1 liter) was immersed in water for 1 hour, and then taken out and weighed. Table 2 shows the amount of water absorbed by dividing the increased weight by the original weight.
叉2
試験例3 吸汗量試験
10名の被験者に本発明の実施例1〜5.11〜19及
び参考例1〜5、比較例として市販の消炎鎮痛プラスタ
ーAの20種を用いて背部に7時間貼付、剥離後、直ち
に重量部を測定し、増加した重量部を元の重量で除し、
増加型N(%)として表わした。2 Test Example 3 Sweat Absorption Test 10 subjects were tested on the back using Examples 1 to 5, 11 to 19 of the present invention and Reference Examples 1 to 5, and 20 types of commercially available anti-inflammatory and analgesic plaster A as a comparative example. After applying for a time and peeling off, immediately measure the weight part, divide the increased weight part by the original weight,
Expressed as incremental N (%).
表3
試験例1.2.3より明らかな如く、本発明の無刺激性
貼付剤は、本発明の如く吸水高分子の配合が必須であり
、その限定された配合により、きねだった吸水力を示し
、また試験例3からも明らかな如く、汗の吸収量も極め
て多い、その結果、参考例及び市販のプラスターに比較
し、はるかに低い皮膚刺激を有し、無刺激性外用貼付剤
としての有用性を充分に示すものである。Table 3 As is clear from Test Example 1.2.3, the non-irritating adhesive patch of the present invention must contain a water-absorbing polymer as in the present invention, and due to its limited formulation, it has excellent water absorption. In addition, as is clear from Test Example 3, the amount of sweat absorbed is extremely high.As a result, compared to reference examples and commercially available plasters, it has far less skin irritation and is a non-irritating topical patch. This fully demonstrates its usefulness as a.
手続補正書(自発)
1.事件の表示
昭和62年 特許願第79317号
2、 発明の名称
外用貼付剤
3、補正をする者
4、補正命令の日付 自発
(1) 明細書中、「3、発明の詳細な説明」の欄の
第5真下から第4行目の「以外」とあるを、「意外」と
訂正する。Procedural amendment (voluntary) 1. Indication of the case 1988 Patent Application No. 79317 2 Name of the invention Topical patch 3 Person making the amendment 4 Date of order for amendment Voluntary action (1) In the specification, "3. Detailed description of the invention" column In the fourth line from the bottom of the fifth line, the word "other than" is corrected to "unexpected."
(2) 同書中、第6真下から第6行目より第5行目
の「吸水あるいはゲル化」とあるを、「吸水ゲル化」と
訂正する。(2) In the same book, the phrase "water absorption or gelation" in lines 6 to 5 from just below the 6th page is corrected to "water absorption or gelation."
(3)同書中、第7買上から第9行目の[アラソーブ8
00FJの次に「キューピー製及び資生堂製等のヒアル
ロン酸又はその塩あるいはその誘導体jを挿入する。(3) In the same book, from the 7th purchase to the 9th line [Arasorb 8
Next to 00FJ, insert hyaluronic acid or its salt or its derivative j manufactured by Kewpie, Shiseido, etc.
(4)同書中、第7真上から第9行目より第10行目の
「好ましくは軽度の架橋結合を導入したものが好適に用
いられる。」を削除する。(4) In the same book, from the 7th line above, the 9th line to the 10th line, ``Preferably, those with a slight cross-linking bond are preferably used.'' are deleted.
(5) 同書中、第7頁下から第7行目の「アラソー
ブFは」とあるを、rアラソーブ800 F、ヒアルロ
ン酸)(A−3等がjと訂正する。(5) In the same book, in the seventh line from the bottom of page 7, the phrase "Arasorb F is" is corrected to rArasorb 800 F, hyaluronic acid) (A-3 etc. is j).
(6) 同書中、第9真下から第7行目の「カンフル
」とあるを、rカンフル(d体、β体、d体)jと訂正
する。(6) In the same book, the word "camphor" in the 7th line from just below the 9th line is corrected to r-camphor (d-form, β-form, d-form)j.
(7)同書中、第15買上から第9行目の「かぶれ」と
あるを、「気触れ(かぶれ)」と訂正する。(7) In the same book, the word ``rash'' in the 9th line from the 15th purchase is corrected to ``rash.''
(8)同書中、第23真上から第9行目の「微粉化した
もの」を削除する。(8) In the same book, the 9th line from just above No. 23, "pulverized" is deleted.
(9) 同書中、第24真下から第4行目の「アラソ
ーブ800FJとあるを、「アラソーブ800F (荒
川化学製)Jと訂正する。(9) In the same book, in the fourth line from the bottom of the 24th line, "Arasorb 800FJ" is corrected to "Arasorb 800F (manufactured by Arakawa Chemical) J.
αφ 同書中、第25真下から第8行目の「アラソーブ
800FJとあるを、「アラソーブ800F (荒川化
学製)」と訂正する。αφ In the same book, in the 8th line from just below No. 25, "Arasorb 800FJ" is corrected to "Arasorb 800F (manufactured by Arakawa Chemical)".
αυ 同書中J第25真下から7行目の「ヒアルロンサ
ンHA−3(キュービ製)」とあるを、「ヒアルロン酸
HA−3(キューピー製)」と訂正する。αυ In the same book, in the 7th line from the bottom of J 25, "Hyaluronic acid HA-3 (manufactured by Kewpie)" is corrected to "Hyaluronic acid HA-3 (manufactured by Kewpie)".
Claims (1)
量%を配合することを特徴とする外用貼付剤。1. An external patch characterized by containing 1 to 20% by weight of a water-absorbing polymer as an essential component in the plaster component.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP25309886 | 1986-10-23 | ||
JP61-253098 | 1986-10-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS63225314A true JPS63225314A (en) | 1988-09-20 |
JP2632838B2 JP2632838B2 (en) | 1997-07-23 |
Family
ID=17246459
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP62079317A Expired - Lifetime JP2632838B2 (en) | 1986-10-23 | 1987-04-01 | External patch |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2632838B2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06205839A (en) * | 1992-12-04 | 1994-07-26 | Pacific Corp | Poultice for percutaneously loading-type medicine |
JP2005097132A (en) * | 2003-09-22 | 2005-04-14 | Hisamitsu Pharmaceut Co Inc | Low-irritant patch |
JP2015108007A (en) * | 1999-04-22 | 2015-06-11 | エルティエス ローマン テラピー−ズュステーメ アーゲー | Transdermal therapeutic system with neutralized acrylic adhesive patch |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56103112A (en) * | 1980-01-18 | 1981-08-18 | Nippon Synthetic Chem Ind Co Ltd:The | Cataplasm |
JPS58105915A (en) * | 1981-12-17 | 1983-06-24 | Lion Corp | Composition for integument |
JPS59104314A (en) * | 1982-11-09 | 1984-06-16 | Hisamitsu Pharmaceut Co Inc | Novel plaster |
-
1987
- 1987-04-01 JP JP62079317A patent/JP2632838B2/en not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56103112A (en) * | 1980-01-18 | 1981-08-18 | Nippon Synthetic Chem Ind Co Ltd:The | Cataplasm |
JPS58105915A (en) * | 1981-12-17 | 1983-06-24 | Lion Corp | Composition for integument |
JPS59104314A (en) * | 1982-11-09 | 1984-06-16 | Hisamitsu Pharmaceut Co Inc | Novel plaster |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06205839A (en) * | 1992-12-04 | 1994-07-26 | Pacific Corp | Poultice for percutaneously loading-type medicine |
JP2015108007A (en) * | 1999-04-22 | 2015-06-11 | エルティエス ローマン テラピー−ズュステーメ アーゲー | Transdermal therapeutic system with neutralized acrylic adhesive patch |
JP2005097132A (en) * | 2003-09-22 | 2005-04-14 | Hisamitsu Pharmaceut Co Inc | Low-irritant patch |
Also Published As
Publication number | Publication date |
---|---|
JP2632838B2 (en) | 1997-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3566301B2 (en) | Supersaturated transdermal drug delivery system and method of manufacturing the same | |
JP4346696B2 (en) | Transdermal therapeutic device | |
JP4593471B2 (en) | Skin patch | |
JPH09511987A (en) | Transdermal member containing polyvinylpyrrolidone as a solubility enhancer | |
AU1891101A (en) | Adhesive preparations | |
WO2001052823A2 (en) | Compositions to effect the release profile in the transdermal administration of drugs | |
JPH09100227A (en) | Solid matrix system for percutaneous drug delivery | |
WO2002032431A1 (en) | Compositions for external preparations | |
WO2000021566A1 (en) | Sorbefacients and preparations for percutaneous absorption containing the same | |
US20090004256A1 (en) | Lowly irritative adhesive patch | |
JP3466305B2 (en) | Dissolving agent and external preparation containing the dissolving agent | |
JP4590418B2 (en) | Anti-inflammatory analgesic patch | |
JPH07206710A (en) | Tape preparation for transcutaneous administration | |
JP3146002B2 (en) | Transdermal formulation | |
WO1999036061A1 (en) | Plasticizer and patch containing the plasticizer | |
JP3144895B2 (en) | Medical adhesive tape or sheet | |
JP2632838B2 (en) | External patch | |
JPH0271745A (en) | Water-contained gel composition | |
JP3199770B2 (en) | Patch for transdermal administration and method for producing the same | |
JPH01297069A (en) | Tacky adhesive agent composition | |
JPH01297059A (en) | Warm heat sticking agent | |
JPH0336806B2 (en) | ||
JPS63203613A (en) | Hydrophilic percutaneous administration preparation | |
EP3744322B1 (en) | Patch | |
JPH0714866B2 (en) | Transdermal patch |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EXPY | Cancellation because of completion of term |